Liver Cancer Drugs Market

The global liver cancer drugs market size is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the presence of strong pipeline, availability of novel drugs, rising awareness among people, growing incidence of liver cancer.

Liver cancer is a cancer that starts in the liver cells. It is a type of chronic disorder which is progressive and life-threatening. Liver cancer is the fifth largest prevalent cancer around the world. There are several types of liver cancer such as primary hepatic cancer and metastatic cancer. In primary hepatic cancer, it begins in hepatocyte cells. In metastatic cancer, it spreads to the liver from other parts of the body. Liver cancer holds around 9% of overall cancer deaths. Around 780,500 new cases were diagnosed in 2012 and 745,500 deaths were occurred because of liver cancer. Due to poor survival rate and aggressive nature the primary liver cancer is one of the most important public health issues.

Hepatocellular carcinomas (HCCs) hold majority of primary liver cancers. A substantial number of etiological factors of liver cancer are hepatitis infection and cirrhosis. These factors present a strong prospect for decreasing the incidences and mortality by using prevention strategies which includes hepatitis immunization and lifestyle modification. Even most systemic drugs are not efficient for the treatment of Liver cancer. Hence, research and developments are majorly focusing on molecular pathways involved in hepatocarcinogenesis.

Liver cancer treatment market is increasing with rising first-in-class developments in novel therapies. Small molecules represent the largest group of drug products in development and licensing deals, after monoclonal antibodies. Huge portion of pipeline products target components of dysfunctional signaling pathway. Innovative treatment methods including RNA interference technology (RNAi) or oncolytic viruses have achieved important traction in the field.

Market Trends, Drivers, Restraints, and Opportunities

• Growing prevalence of liver cancer and availability of novel drugs are major factors responsible for the growth of the market over the forecast period.
• Increasing investment on research and development sector and rising development of novel therapies are expected to fuel the market growth in the coming years.
• Rising initiatives by government and presence of strong pipeline are projected to drive the expansion of the market.
• Increasing awareness about cancer among people is factor that can propel the market growth during the forecast period.
• Growing geriatric population and changing lifestyle are anticipated to push the market growth in the coming years.
• High cost of cancer therapies and side effects of drugs are major factor responsible for hampering the growth of the market in the coming years.
• Stringent regulation is projected to impede the market expansion over the forecast period.

Scope of the Report

The report on the global liver cancer drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Targeted therapy segment is projected to hold key market share
Based on therapeutic classes, the liver cancer drugs market is bifurcated into targeted therapy and immunotherapy. The targeted therapy segment is expected to hold a key share of the market during the forecast period. The best treatment for HCC is partial surgical resection. The risk of fatal complications such as liver failure increases due to resection of cirrhotic livers. The relapse rate after this surgery is high. However, the rate of survival is improved significantly. Nexavar is the only approved targeted therapy for the advanced HCC patients.

On the other hand, the immunotherapy segment is anticipated to expand at a rapid pace during the forecast period. Immunotherapy fights with cancer cells by using human immune system. In this type several drugs are present across the globe. The immunotherapy segment comprises of checkpoint inhibitors and targeted antibodies. Increasing research and development, rising awareness about cancer therapeutics among people, and advantages of immunotherapy are expected to drive the growth of the segment.

North America is expected to dominate the market
On the basis of regions, the liver cancer drugs market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to launch of novel products, increasing adoption of novel therapeutics, and presence of a large target population. In U.S., rising R&D activities are anticipated to drive the regional market growth. The Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) and bevacizumab (Avastin) in May 2020. This approval was for initial treatment of people having liver cancer which is spread and can’t be treated with surgery.

However, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years due to rising incidences of liver cancer, presence of huge base of targeted population, and strong unmet clinical needs.

Segments

• Targeted Therapy
• Immunotherapy

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

• Bayer
• Bristol-Myers Squibb
• Eisai
• Exelixis
• Merck
• AstraZeneca
• Eli Lilly
• Amgen
• Pfizer Inc.
• Novartis AG
• SillaJen

Competitive Landscape